175 related articles for article (PubMed ID: 35315496)
1. Elevation of ADAM12 facilitates tumor progression by enhancing metastasis and immune infiltration in gastric cancer.
Zhu H; Jiang W; Zhu H; Hu J; Tang B; Zhou Z; He X
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315496
[TBL] [Abstract][Full Text] [Related]
2. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.
Gao J; Yang D; Xu H; Yang K; Ma J; Xia J; Pan X
Bioengineered; 2022 Feb; 13(2):2412-2429. PubMed ID: 35094638
[TBL] [Abstract][Full Text] [Related]
3. Expression of
Chung MW; Park YL; Park SY; Joo YE
In Vivo; 2022; 36(5):2194-2204. PubMed ID: 36099146
[TBL] [Abstract][Full Text] [Related]
4. A novel ceRNA axis involves in regulating immune infiltrates and macrophage polarization in gastric cancer.
Nie K; Zheng Z; Wen Y; Pan J; Liu Y; Jiang X; Yan Y; Jiang K; Liu P; Xu S; Liu F; Li P
Int Immunopharmacol; 2020 Oct; 87():106845. PubMed ID: 32763781
[TBL] [Abstract][Full Text] [Related]
5. An ADAM12 and FAK positive feedback loop amplifies the interaction signal of tumor cells with extracellular matrix to promote esophageal cancer metastasis.
Luo ML; Zhou Z; Sun L; Yu L; Sun L; Liu J; Yang Z; Ran Y; Yao Y; Hu H
Cancer Lett; 2018 May; 422():118-128. PubMed ID: 29476791
[TBL] [Abstract][Full Text] [Related]
6. Effects and prognostic values of miR-30c-5p target genes in gastric cancer via a comprehensive analysis using bioinformatics.
Hu S; Liu H; Zhang J; Li S; Zhou H; Gao Y
Sci Rep; 2021 Oct; 11(1):20584. PubMed ID: 34663825
[TBL] [Abstract][Full Text] [Related]
7.
Pan J; Huang Z; Zhang Y; Xu Y
DNA Cell Biol; 2022 Apr; 41(4):410-423. PubMed ID: 35377217
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of ADAM12 Is Associated With a Poor Survival and Immune Cell Infiltration in Colon Adenocarcinoma.
Huang Z; Lai H; Liao J; Cai J; Li B; Meng L; Wang W; Mo X; Qin H
Front Oncol; 2021; 11():729230. PubMed ID: 34604068
[TBL] [Abstract][Full Text] [Related]
9. MTFR2, A Potential Biomarker for Prognosis and Immune Infiltrates, Promotes Progression of Gastric Cancer Based on Bioinformatics Analysis and Experiments.
Zhu H; Wang G; Zhu H; Xu A
J Cancer; 2021; 12(12):3611-3625. PubMed ID: 33995638
[No Abstract] [Full Text] [Related]
10. Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer.
Zhu L; Wang Z; Han W; Xu A
BMC Gastroenterol; 2023 Mar; 23(1):74. PubMed ID: 36918802
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
12. ADAM12 is an independent predictor of poor prognosis in liver cancer.
Du S; Sun L; Wang Y; Zhu W; Gao J; Pei W; Zhang Y
Sci Rep; 2022 Apr; 12(1):6634. PubMed ID: 35459884
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells.
Zhou Y; Xiong L; Zhang Y; Yu R; Jiang X; Xu G
J Proteomics; 2016 Oct; 148():94-104. PubMed ID: 27432471
[TBL] [Abstract][Full Text] [Related]
14. EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer.
Ke B; Liang ZK; Li B; Wang XJ; Liu N; Liang H; Zhang RP
PeerJ; 2023; 11():e15559. PubMed ID: 37576496
[TBL] [Abstract][Full Text] [Related]
15. Follistatin-like 1 (FSTL1) is a prognostic biomarker and correlated with immune cell infiltration in gastric cancer.
Li L; Huang S; Yao Y; Chen J; Li J; Xiang X; Deng J; Xiong J
World J Surg Oncol; 2020 Dec; 18(1):324. PubMed ID: 33292276
[TBL] [Abstract][Full Text] [Related]
16. ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer.
Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Azúa YR; Aguiar B; Beloqui R; Armendáriz P; Arriola M; Martín-Sánchez E; Guerrero-Setas D
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019179
[TBL] [Abstract][Full Text] [Related]
17.
Liu YJ; Li JP; Zhang Y; Nie MJ; Zhang YH; Liu SL; Zou X
Onco Targets Ther; 2021; 14():4099-4117. PubMed ID: 34262295
[TBL] [Abstract][Full Text] [Related]
18. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a.
Huang X; Xie X; Liu P; Yang L; Chen B; Song C; Tang H; Xie X
Oncogene; 2018 Dec; 37(49):6316-6326. PubMed ID: 30042416
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of FSTL3, ADAM12, and FAT4 in Patients of Colon Cancer: Clinicopathologic Study.
Ibrahim HM; Abdelrahman AE; Elwan A; Bakry A; Fahmy MM; Abdelhamid MI; Abdelwanis AH; Fouad EM
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):673-681. PubMed ID: 37751246
[TBL] [Abstract][Full Text] [Related]
20. ALDOC regulated the biological function and immune infiltration of gastric cancer cells.
Chen L; Zeng Y; Ren B; Wang X; Zhao F; Du J; Zhang R; Deng J
Int J Biochem Cell Biol; 2023 May; 158():106407. PubMed ID: 36997056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
